Zhang Y, Wu Y, Zhang K, et al. - Researchers undertook this prospective, controlled, single-center study to assess the impacts of early use of Sacubitril/Valsartan (Sac/Val) in patients with ST-elevation myocardial infarction following primary percutaneous coronary intervention (pPCI). This analysis involved 186 patients. Participants were randomly assigned to either Sac/Val group: early use of Sac/Val within 24 hours post-pPCI; or control group: conventional angiotensin-converting enzyme inhibitors (ACEI) use. Relative to the control group, Sac/Val could afford reduction in the creatine kinase peak as well as in the incidence of acute heart failure post-pPCI; the concentration of NT-proBNP was lower and left ventricular ejection fraction was higher prior to discharge in the Sac/Val group. Findings indicate that early administration of Sacubitril/Valsartan could be beneficial for patients with ST-elevation myocardial infarction post-primary percutaneous coronary intervention; the impact was superior to conventional ACEI.